Published in Medicine (Baltimore) on September 01, 2015
The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology (1997) 13.27
Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol (1994) 10.03
Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem (2004) 4.31
Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med (1999) 3.63
A systematic review of the association between erectile dysfunction and cardiovascular disease. Eur Urol (2013) 3.12
Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int J Impot Res (2000) 2.64
Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation (1997) 2.00
Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost (1999) 1.46
Anatomy, physiology, and pathophysiology of erectile dysfunction. J Sex Med (2010) 1.35
Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. Arch Intern Med (1999) 1.14
Plasma homocysteine predicts progression of atherosclerosis. Atherosclerosis (2005) 1.07
The endothelial-erectile dysfunction connection: an essential update. J Sex Med (2009) 1.03
Standardization of vascular assessment of erectile dysfunction: standard operating procedures for duplex ultrasound. J Sex Med (2012) 0.96
Endothelial dysfunction: the link between homocysteine and hydrogen sulfide. Curr Med Chem (2014) 0.87
Prevalence and associations of erectile dysfunction in a sample of Italian males with type 2 diabetes. Diabetes Res Clin Pract (2015) 0.83
Hyperhomocysteinemia: a novel risk factor for erectile dysfunction. Metabolism (2006) 0.83
The interaction of homocysteine and copper markedly inhibits the relaxation of rabbit corpus cavernosum: new risk factors for angiopathic erectile dysfunction? BJU Int (1999) 0.81
Treatment of erectile dysfunction due to C677T mutation of the MTHFR gene with vitamin B6 and folic acid in patients non responders to PDE5i. J Sex Med (2009) 0.80
Erectile dysfunction as a coronary artery disease risk equivalent. J Nucl Cardiol (2008) 0.80
Erectile dysfunction: does insulin resistance play a part? Fertil Steril (2007) 0.80
Icariside II prevents high-glucose-induced injury on human cavernous endothelial cells through Akt-eNOS signaling pathway. Andrology (2015) 0.78
Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol (2007) 3.26
Calcitriol: a better option than vitamin D in denosumab-treated patients with kidney failure? Expert Opin Biol Ther (2012) 2.27
Treatment of varicocele in subfertile men: The Cochrane Review--a contrary opinion. Eur Urol (2006) 2.18
Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol (2003) 2.17
Assessing the accuracy and generalizability of the preoperative and postoperative Karakiewicz nomograms for renal cell carcinoma: results from a multicentre European and US study. BJU Int (2013) 2.08
Prostate cancer gene 3 and multiparametric magnetic resonance can reduce unnecessary biopsies: decision curve analysis to evaluate predictive models. Urology (2013) 2.07
Sipuleucel-T (Provenge®) for castration-resistant prostate cancer. BJU Int (2011) 1.61
Endothelial-to-mesenchymal transition and renal fibrosis in ischaemia/reperfusion injury are mediated by complement anaphylatoxins and Akt pathway. Nephrol Dial Transplant (2014) 1.61
Inflammation and chronic prostatic diseases: evidence for a link? Eur Urol (2007) 1.61
Prostate cancer recurrence after radical prostatectomy: the role of 3-T diffusion imaging in multi-parametric magnetic resonance imaging. Eur Radiol (2013) 1.60
Smoking as a risk factor for erectile dysfunction: data from the Andrology Prevention Weeks 2001-2002 a study of the Italian Society of Andrology (s.I.a.). Eur Urol (2005) 1.52
Factors predicting continence recovery 1 month after radical prostatectomy: results of a multicenter survey. Int J Urol (2011) 1.49
Prostate size does not predict high grade cancer. J Urol (2011) 1.46
Thulium laser supported nephron sparing surgery for renal cell carcinoma. J Urol (2013) 1.28
Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer. Anticancer Res (2003) 1.27
Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys (2011) 1.26
Two-sided bulbar urethroplasty using dorsal plus ventral oral graft: urinary and sexual outcomes of a new technique. J Urol (2011) 1.20
Risk factors for emotional and relationship problems in Peyronie's disease. J Sex Med (2008) 1.14
Therapeutic targeting of classical and lectin pathways of complement protects from ischemia-reperfusion-induced renal damage. Am J Pathol (2010) 1.12
Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml. PLoS One (2013) 1.09
Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). Eur J Radiol (2011) 1.09
Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU Int (2011) 1.05
Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy. Clin Cancer Res (2010) 1.04
MR and CT image fusion for postimplant analysis in permanent prostate seed implants. Int J Radiat Oncol Biol Phys (2004) 1.04
Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. Prostate (2012) 1.03
Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. BJU Int (2012) 1.00
Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. Int J Cancer (2014) 1.00
Testicular granulosa cell tumor of adult type: a new case and a review of the literature. Urol Oncol (2007) 0.99
The protonophore CCCP interferes with lysosomal degradation of autophagic cargo in yeast and mammalian cells. Autophagy (2013) 0.98
Metabolomic profiling for the identification of novel diagnostic markers in prostate cancer. Expert Rev Mol Diagn (2015) 0.98
Synchronous collecting duct carcinoma and papillary renal cell carcinoma: a case report and review of the literature. Anticancer Res (2005) 0.98
Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. Future Oncol (2013) 0.96
Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer. Anticancer Res (2006) 0.95
Pre-existing type 2 diabetes mellitus is an independent risk factor for mortality and progression in patients with renal cell carcinoma. Medicine (Baltimore) (2014) 0.94
Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer. Int J Cancer (2014) 0.94
Gender differences in clinicopathological features and survival in surgically treated patients with renal cell carcinoma: an analysis of the multicenter CORONA database. World J Urol (2013) 0.94
Patient and partner satisfaction after AMS inflatable penile prosthesis implant. J Sex Med (2009) 0.94
Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. Eur Urol (2011) 0.93
Magnetic resonance spectroscopic imaging (1H-MRSI) and dynamic contrast-enhanced magnetic resonance (DCE-MRI): pattern changes from inflammation to prostate cancer. Cancer Invest (2010) 0.92
Clinical and pathological outcomes of renal cell carcinoma (RCC) in native kidneys of patients with end-stage renal disease: a long-term comparative retrospective study with RCC diagnosed in the general population. World J Urol (2014) 0.92
Unusual solitary metastasis of the ciliary body in renal cell carcinoma. Int J Urol (2008) 0.92
Long term patient satisfaction and quality of life with AMS700CX inflatable penile prosthesis. Arch Ital Urol Androl (2013) 0.89
Prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancer. BJU Int (2010) 0.89
The role of renal surgery in the era of targeted therapy: the urologist's perspective. Urologia (2015) 0.89
The emerging role of targeted therapy in renal cell carcinoma (RCC): is it time for a neoadjuvant or an adjuvant approach? Crit Rev Oncol Hematol (2011) 0.88
Early recovery of urinary continence after radical prostatectomy using early pelvic floor electrical stimulation and biofeedback associated treatment. J Urol (2009) 0.88
Sipuleucel-T for prostate cancer: the immunotherapy era has commenced. Expert Rev Anticancer Ther (2011) 0.88
Transabdominal ultrasonography, computed tomography and electronic portal imaging for 3-dimensional conformal radiotherapy for prostate cancer. Strahlenther Onkol (2007) 0.88
Hem-o-lok clip: a neglected cause of severe bladder neck contracture and consequent urinary incontinence after robot-assisted laparoscopic radical prostatectomy. BMC Urol (2014) 0.87
Linac-based stereotactic body radiotherapy for oligometastatic patients with single abdominal lymph node recurrent cancer. Am J Clin Oncol (2014) 0.87
Matrix metalloproteinase-2 and -9 in the urine of prostate cancer patients. Oncol Rep (2010) 0.86
Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients. Cancer Chemother Pharmacol (2011) 0.86
Prognostic effect of sarcomatoid dedifferentiation in patients with surgically treated renal cell carcinoma: a matched-pair analysis. Clin Genitourin Cancer (2013) 0.85
Third-Line Chemotherapy for Metastatic Urothelial Cancer: A Retrospective Observational Study. Medicine (Baltimore) (2015) 0.85
Superselective embolization of bladder arteries in the treatment of intractable bladder haemorrhage. Int J Urol (2005) 0.85
Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction. BJU Int (2004) 0.85
Supernumerary kidney laparoscopically treated. Can Urol Assoc J (2013) 0.85
Management of urethral stent failure for recurrent anterior urethral strictures. Eur Urol (2009) 0.85
Image guided hypofractionated radiotherapy and quality of life for localized prostate cancer: prospective longitudinal study in 337 patients. J Urol (2013) 0.85
Randomized trial comparing an anterograde versus a retrograde approach to open radical prostatectomy: results in terms of positive margin rate. Can Urol Assoc J (2010) 0.85
Peg-filgrastim and cabazitaxel in prostate cancer patients. Anticancer Drugs (2013) 0.85
Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content. Oncol Rep (2010) 0.85
Urethral pseudodiverticulum secondary to penile fracture and complete urethra dissection. Can Urol Assoc J (2013) 0.84
"Burned out" phenomenon of the testis in retroperitoneal seminoma. Acta Oncol (2006) 0.84
Paternal aging and increased risk of congenital disease, psychiatric disorders, and cancer. Asian J Androl (2016) 0.84
Basaloid cell carcinoma of the prostate. Virchows Arch (2003) 0.84
Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retropective study. J Transl Med (2013) 0.84
Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients. Anticancer Drugs (2009) 0.84
In vivo 3D neuroanatomical evaluation of periprostatic nerve plexus with 3T-MR Diffusion Tensor Imaging. Eur J Radiol (2013) 0.84
Modern role of magnetic resonance and spectroscopy in the imaging of prostate cancer. Urol Oncol (2009) 0.84
European Study of Radical Prostatectomy: time trends in Europe, 1993-2005. BJU Int (2007) 0.83
A single-center cohort study to define the role of pretransplant biopsy score in the long-term outcome of kidney transplantation. Transplantation (2014) 0.83
Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy: A Multicenter Experience. Medicine (Baltimore) (2015) 0.83
[Role of neuroendocrine cells in prostate cancer progression]. Urologia (2011) 0.83
Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection. Urol Oncol (2011) 0.83
Distribution of high chromogranin A serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma. Urol Int (2009) 0.83
Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma. Prostate (2003) 0.83
Simultaneous total corporal reconstruction and implantation of a penile prosthesis in patients with erectile dysfunction and severe fibrosis of the corpora cavernosa. J Sex Med (2012) 0.83
The surgical treatment of a large prostatic adenoma: the laparoscopic approach--a systematic review. J Endourol (2012) 0.83
MR imaging and cognitive correlates of relapsing-remitting multiple sclerosis patients with cerebellar symptoms. J Neurol (2012) 0.82
Treatment of ureterointestinal anastomotic strictures by diathermal or cryoplastic dilatation. Cardiovasc Intervent Radiol (2007) 0.82
Androgen deprivation therapy affects BCL-2 expression in human prostate cancer. Int J Oncol (2011) 0.82
The epidermal growth factor receptors as biological targets in penile cancer. Expert Opin Biol Ther (2014) 0.82
Premature ejaculation results in female sexual distress: standardization and validation of a new diagnostic tool for sexual distress. J Urol (2012) 0.82
Acute toxicity of image-guided hypofractionated radiotherapy for prostate cancer: nonrandomized comparison with conventional fractionation. Urol Oncol (2009) 0.82
Comparative analysis of multiparametric magnetic resonance and PET-CT in the management of local recurrence after radical prostatectomy for prostate cancer. Crit Rev Oncol Hematol (2012) 0.82